| Authors |
Kubica, Jacek ; Adamski, Piotr ; Badarienė, Jolita ; Bonaca, Marc ; Buszman, Piotr ; Gabulova, Rahima ; Gajda, Robert ; Geisler, Tobias ; Gil, Robert ; Gorog, Diana A ; Gurbel, Paul A ; Hajdukiewicz, Tomasz ; Hudzik, Bartosz ; James, Stefan ; Jeong, Young-Hoon ; Kern, Adam ; Kochman, Wacław ; Kubica, Aldona ; Kuliczkowski, Wiktor ; Magielski, Przemysław ; Niezgoda, Piotr ; Ostrowska, Małgorzata ; Raggi, Paolo ; Rahimov, Uzeyir ; Skonieczny, Grzegorz ; Siller-Matula, Jolanta M ; Specchia, Giuseppe ; Szarpak, Łukasz ; Szymański, Paweł ; Tantry, Udaya ; Umińska, Julia ; Navarese, Eliano Pio |
| Abstract [eng] |
The 2023 ESC guidelines changed the previously recommended strategy of early treatment in patients with STEMI. Pre-treatment with a P2Y12 receptor inhibitor may be considered in patients undergoing a primary PCI strategy (Class IIb, Level of evidence B). However, the available scientific evidence justifies a personalized approach differentiating the indications for pre-treatment with oral P2Y12 receptor inhibitors depending on the concomitant administration of opioids. In our opinion, in patients undergoing primary PCI not treated with opioids, pre-treatment with an oral P2Y12 receptor inhibitor should be applied, while in patients undergoing primary PCI treated with opioids, pre-treatment with an oral P2Y12 receptor inhibitor should be considered. (Cardiol J 2025; 32, 2: 189–194). |
